Clinical Research Article

Association of Metformin with Susceptibility to COVID-19 in People with Type 2 Diabetes

Jingya Wang, 1, * Jennifer M. Cooper, 1, * Krishna Gokhale, 1, Dionisio Acosta-Mena, 2, Samir Dhalla, 3, Nathan Byne, 2, Joht Singh Chandan, 1, Astha Anand, 1, Kelvin Okoth, 1, Anuradhaa Subramanian, 1, Mansoor N. Bangash, 4, 5 Thomas Jackson, 6, Dawit Zemedikun, 1, Tom Tavener, 1, Wasim Hanif, 7, Sandip Ghosh, 7, Parth Narendran, 7, 8 Konstantinos A. Toulis, 1, Abd A. Tahran, 7, 9, 10 Rajendra Surentirakumaran, 11, Nicola J. Adderley, 1, Shamir Haroon, 1, Kamlesh Khunti, 12, Christopher Sainsbury, 1, 13, 14 G. Neil Thomas, 1, 1, # and Krishnarajah Niranarajakumar 1, 1, 14

1 Institute of Applied Health Research, University of Birmingham, Birmingham B15 2TT, UK; 2 Cegedim Health Data, Cegedim Rx, London SW8 3QJ, UK; 3 The Health Improvement Network (THIN), London N1 9JY, UK; 4 Institute of Clinical Sciences, University of Birmingham, Birmingham B15 2TT, UK; 5 Department of Critical Care, University Hospitals Birmingham NHS Foundation Trust, Birmingham B15 2TH, UK; 6 Institute of Inflammation and Ageing, University of Birmingham, Birmingham B15 2TT, UK; 7 Department of Diabetes and Endocrinology, University Hospitals Birmingham NHS Foundation Trust, Birmingham B15 2TH, UK; 8 Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham B15 2TT, UK; 9 Institute of Metabolism and Systems Research, University Hospitals Birmingham NHS Foundation Trust, Birmingham B15 2TH, UK; 9 Centre for Endocrinology, Diabetes and Metabolism (CEDAM), Birmingham Health Partners, Birmingham B15 2TT, UK; 10 Department of Community and Family Medicine, Faculty of Medicine, University of Jaffna, Jaffna 40000, Sri Lanka; 11 Department of Diabetes, Gartnavel General Hospital, NHS Greater Glasgow and Clyde, Glasgow G12 0XH, UK; and 12 Department of Diabetes, Gartnavel General Hospital, NHS Greater Glasgow and Clyde, Glasgow G12 0XH, UK

ORCiD numbers: 0000-0003-1498-2693 (J. Wang); 0000-0002-9561-5141 (J. S. Chandan); 0000-0002-2745-4083 (K. Okoth); 0000-0001-5039-5184 (M. N. Bangash); 0000-0001-6230-9600 (T. Jackson); 0000-0003-3642-0456 (D. Zemedikun); 0000-0002-2044-4253 (K. A. Toulis); 0000-0001-9037-1937 (A. A. Tahran); 0000-0003-0543-3254 (N. Adderley); 0000-0002-0996-1413 (S. Haroon); 0000-0003-2343-7099 (K. Khunti); 0000-0002-2777-1847 (G. N. Thomas).

* Contributed equally.

#Joint Senior Authors.

Abbreviations: ACE2, angiotensin converting enzyme 2; AMPK, adenosine monophosphate–activated protein kinase; BMI, body mass index; DPP4, dipeptidyl peptidase 4; eGFR, estimated glomerular filtration rate; GLP-1, glucagon-like peptide-1; HbA1c, glycated hemoglobin; HDL-C, high-density lipoprotein cholesterol; NAFLD, nonalcoholic fatty liver disease; NASH, nonalcoholic steatohepatitis; SGLT2, sodium-glucose cotransporter 2; THIN, The Health Improvement Network.

Received: 23 December 2020; Editorial Decision: 28 January 2021; First Published Online: 29 January 2021; Corrected and Typeset: 22 March 2021.

Abstract

Objective: Diabetes has emerged as an important risk factor for mortality from COVID-19. Metformin, the most commonly prescribed glucose-lowering agent, has been proposed...
to influence susceptibility to and outcomes of COVID-19 via multiple mechanisms. We investigated whether, in patients with diabetes, metformin is associated with susceptibility to COVID-19 and its outcomes.

**Research Design and Methods:** We performed a propensity score–matched cohort study with active comparators using a large UK primary care dataset. Adults with type 2 diabetes patients and a current prescription for metformin and other glucose-lowering agents (MF+) were compared to those with a current prescription for glucose-lowering agents that did not include metformin (MF–). Outcomes were confirmed COVID-19, suspected/confirmed COVID-19, and associated mortality. A negative control outcome analysis (back pain) was also performed.

**Results:** There were 29,558 and 10,271 patients in the MF+ and MF– groups, respectively, who met the inclusion criteria. In the propensity score–matched analysis, the adjusted hazard ratios for suspected/confirmed COVID-19, confirmed COVID-19, and COVID-19-related mortality were 0.85 (95% CI 0.67, 1.08), 0.80 (95% CI 0.49, 1.30), and 0.87 (95% CI 0.34, 2.20) respectively. The negative outcome control analysis did not suggest unobserved confounding.

**Conclusion:** Current prescription of metformin was not associated with the risk of COVID-19 or COVID-19-related mortality. It is safe to continue prescribing metformin to improve glycemic control in patients with.

**Key Words:** type 2 diabetes mellitus, metformin, COVID-19, SARS-CoV-2 infection
Current “sick-day rules” guidelines advise metformin should be discontinued by patients hospitalized for acute illnesses (22). Metformin may increase the risk of lactic acidosis or acute kidney injury in severe COVID-19 (18), especially if it exacerbates gastrointestinal symptoms (22). This guidance has been reiterated by National Health Service (NHS) England for COVID-19 (23).

Given the proposed mechanisms by which metformin might impact susceptibility to COVID-19, we aimed to investigate in a primary care–based type 2 diabetes patient cohort the risk of confirmed or suspected COVID-19 with current metformin prescription to those with a history or absence of a metformin prescription.

Methods

Study Design

A population-based retrospective cohort study of adults with type 2 diabetes comparing those with current prescription of metformin and at least another glucose-lowering agent (MF+) with those with a current prescription of other glucose-lowering agents that does not include metformin (MF−). Data source and methods are broadly similar to our recent publication investigating the susceptibility to COVID-19 in patients prescribed with sodium-glucose cotransporter 2 (SGLT2) in comparison with dipeptidyl peptidase 4 (DPP4) inhibitors (24).

Data Source

The data for this cohort study was derived from The Health Improvement Network (THIN), which contains computerized primary records covering approximately 2.1 million active participants from 365 general practices that used Vision electronic medical records software across the UK in 2020 (25). In terms of demographic structure and common morbidity prevalence, THIN has been demonstrated to be representative of the UK population (25). Within THIN, information relating to symptoms, examinations, investigations, and diagnoses are recorded as Read codes, a hierarchical clinical coding system that is updated in response to new medical knowledge and requests from clinicians (26). Prescriptions are recorded based on the dictionary of medicines and devices (dm + d) and Anatomical Therapeutic Classification (ATC) systems (27). To improve data quality, general practices were eligible to be included in this study from the later of 12 months after the installation of Vision software and 12 months after reporting acceptable mortality rates (28).

Study Population

Adults (≥18 years of age) with a record of type 2 diabetes and registered with an eligible general practice no later than January 30, 2019 (1 year before the index date) were eligible for this study. Any individual who was diagnosed with diabetes before the age of 12 years, with a record of type 1 diabetes, adverse reaction to glucose-lowering agents, pancreatitis, estimated glomerular filtration rate (eGFR) measurement less than 30mL/min/1.73m² before the index date, or pregnancy in the preceding year, was excluded. Type 2 diabetes were identified by Read code diagnoses (Supplementary file S1) (30), which have been previously validated within this dataset (29, 30).

Definitions of Glucose-Lowering Agents

Glucose-lowering agent users were defined as individuals with a record of 1 of the following 9 prescriptions: metformin, SGLT2 inhibitors, DPP4 inhibitors, glucagon-like peptide-1 (GLP-1), insulin, sulfonylureas, meglitinides, thiazolidinedione, and acarbose. For each glucose-lowering agent, participants were classified into 4 mutually exclusive categories: current users (prescription continuing beyond the index date), recent users (prescription within 90 days preceding the index date), historical users (prescription ended at least 90 days preceding the index date), and nonusers.

Inclusion and Exclusion Criteria for Metformin Cohort (Exposed Cohort)

To be included in the exposed cohort (MF+), patients should be on a current metformin prescription (extending into the pandemic period) and co-prescribed at least 1 of 8 other glucose-lowering agents. Patients who were on metformin monotherapy were excluded as they would be at an early disease status, resulting in immortal time bias (31).

Inclusion and Exclusion Criteria for Comparator Medication Cohort (Unexposed Cohort)

To be included in the unexposed cohort (MF−), patients should not be a current or recent user of metformin and should have a prescription for at least 1 of the 8 other glucose-lowering agents extending into the pandemic period.

Matching

Individuals in the exposed groups were propensity score–matched to individuals in the comparator group.
Variables used for estimating propensity score for use of metformin (MF+) included: sociodemographic characteristics including age and sex; lifestyle and metabolic profile measures including body mass index (BMI), smoking status, alcoholism, systolic and diastolic blood pressure, total cholesterol, high-density lipoprotein cholesterol (HDL-C), albumin-creatinine ratio (ACR), eGFR, and glycated hemoglobin (HbA1c); presence of comorbidities, including atrial fibrillation, hypertension, cardiovascular diseases (ischemic heart disease, heart failure, stroke/transient ischemic attack, and peripheral vascular disease), and rheumatoid arthritis; comorbidities identified as risk factors for COVID-19, including respiratory diseases, cancers, and rare metabolic disorders; diabetes complications or measures indicating diabetes severity, including microvascular conditions (peripheral neuropathy, diabetes-related foot disease, sight-threatening retinopathy); diabetes duration; and history of prescriptions of relevant drugs including renin-angiotensin-aldosterone system (RAAS) inhibitors, other antihypertensive drugs, lipid-lowering drugs, antiplatelets, anticoagulants, immunosuppressant therapies (including oral corticosteroids), and prescription status of individual glucose-lowering agent (SGLT2 inhibitors, DPP4 inhibitors, GLP-1, insulin, sulfonylureas, meglitinides, thiazolidinedione, and acarbose). Multiple imputation by groups method was used for missing data of all continuous variables (BMI, systolic and diastolic blood pressure, total cholesterol, HDL-C, albumin-creatinine ratio, eGFR, and HbA1c), with 5 simulated complete datasets being created, under the assumption of missing at random. For each simulated complete dataset, individuals in the exposed group were then matched 1:1 to individuals in the comparator group by propensity score using the nearest neighbor algorithm. To ensure positivity (having adequate variation in the treatment of interest within confounder strata), propensity scores were truncated and only participants with propensity scores that lay on the common support with a caliper width of 0.2 were eligible for matching (32). Following matching, each of the imputed propensity score–matched dataset was independently analyzed by standard methods and the results combined in a straightforward manner to produce estimates and CIs that incorporate missing-data uncertainty, using the Rubin rules.

Follow-Up Period

Individuals were followed up from January 30, 2020 (index date) until the earliest date of the following events: outcome of interest, death, individual left practice, practice ceased contributing to the database, or study end date (October 13, 2020).

Outcome

Outcomes were composite of confirmed and clinically suspected diagnosis of COVID-19, confirmed COVID-19, and COVID-19-related deaths, and all-cause mortality. COVID-19-related death was defined as individuals who died within 28 days after the diagnosis of suspected or confirmed COVID-19. A negative control outcome—incident back pain (a common presentation in primary care)—during follow-up was used to evaluate the possibility of surveillance bias and unobserved confounding bias (33). We chose back pain as a negative outcome, considering it a common presentation in primary care and is not associated with the exposure or outcome of interest. All outcomes were defined by the relevant clinical (Read) codes (Supplementary file S2) (30). In the UK, positive reverse transcription polymerase chain reaction (RT-PCR) swab results or positive antibody tests are defined as confirmed COVID-19. Clinicians entered a suspected COVID-19 code where there was no RT-PCR/antibody testing available but a clinical picture was consistent with this infection, confirmation with other investigations (eg, imaging) and/or the patient had been in contact with a confirmed case.

Covariates

The covariate data recorded prior to the index date were obtained and used for propensity score matching and adjustment in the outcome model. Individuals’ BMIs were classified using World Health Organization criteria as follows: underweight or normal weight (BMI of <25 kg/m²), overweight (BMI of 25 kg/m² to <30 kg/m²), and obesity (BMI of ≥30 kg/m²). Smoking status was classified as nonsmokers, ex-smokers, or current smokers. Comorbid conditions and diabetes complications were defined by coded diagnoses (Read codes) recorded in THIN. Comorbid conditions included atrial fibrillation, hypertension, cardiovascular diseases (ischemic heart disease, heart failure, stroke/transient ischemic attack, and peripheral vascular disease), rheumatoid arthritis, respiratory diseases, cancers, nonalcoholic fatty liver disease or nonalcoholic steatohepatitis (NAFLD/NASH), and rare metabolic disorders. Physiological/laboratory measurements were categorized based on clinically meaningful thresholds. Missing data for smoking status and physiological/laboratory measurements were treated as a separate missing category for each variable. The absence of a record of any diagnosis or prescription was taken to indicate the absence of these conditions or medications, respectively.
Statistical Analysis

Baseline characteristics of individuals in the exposed and comparator groups were reported using appropriate descriptive statistics (mean for normally distributed continuous variables and proportions for categorical variables) before and after propensity score matching. Histograms of propensity scores were generated before and after matching for a visual check of the global balance of propensity scores between groups.

Crude incidence rate per 1000 person-years of the outcome of interest and the negative control outcome were estimated for the exposed and the comparator groups. Cox proportional hazards regression models were used to calculate the crude and adjusted hazard ratios, together with their corresponding 95% CIs. Other than rare metabolic conditions (excluded due to the limited number), systolic and diastolic blood pressure (to avoid double adjustment alongside hypertension diagnosis), and prescription status of glucose-lowering agent, all variables listed for propensity score matching and NAFLD/NASH were included in the Cox models for the unmatched analyses. Additionally, we used a composite of cardiovascular conditions and a composite of diabetes complications instead of their individual components in the Cox model adjustment. Survival curves of exposed and comparator groups were generated for both the unmatched and the propensity score–matched cohorts.

A sensitivity analysis limiting the unexposed cohort to those who have previously used metformin but discontinued was performed to eliminate the potential selection bias induced by patients who have not been prescribed metformin before. As metformin might have different performance in different populations, subgroup analyses were also conducted in female, male, individuals with a BMI value ≥ 25 kg/m², and those with a BMI value ≥ 30 kg/m², respectively.

Results

There were 29,558 individuals with a current prescription of metformin (MF+) (exposed group) and 10,271 individuals with a current prescription of other glucose-lowering agents (MF−) (comparator group). Figure 1 shows the flow chart of participant selection procedure for this study.

Baseline Characteristics

In the unmatched cohort, individuals with a current prescription of metformin with other glucose-lowering agents (MF+) were younger (mean age 64.8 vs 67.8 years), had a greater proportion of males (61.9% vs 52.0%), slightly higher BMI value (mean BMI 32.1 vs 31.8 kg/m²), and a lower prevalence of comorbidities, and longer mean duration of diabetes (12.1 vs 11.6 years), compared with individuals with a current prescription that does not include metformin (MF− comparator group) (Table 1).

Following propensity score matching, 10,183 individuals of the metformin group (MF+) were compared with 10,183 individuals in the comparator group (MF−). The baseline characteristics of the exposed (MF+) and comparator (MF−) groups, including demographic and behavioral risk factors, diabetes duration, diabetes complications, comorbidities, metabolic profile, and prior prescriptions, were generally similar in all 5 imputed propensity score–matched datasets (Table 1, Supplementary file S4) (30). Although individuals in the exposed group (MF+) still had a lower prevalence of chronic kidney disease (18.1% vs 23.8% in the first imputed propensity score–matched dataset) compared with the comparator group (MF−), the imbalance between the groups from the unmatched cohort was largely mitigated.

Suspected or Confirmed COVID-19

There were 415 individuals (110 were confirmed COVID-19) in the exposed group (MF+) and 188 individuals (54 were confirmed COVID-19) in the comparator group (MF−) who were diagnosed with suspected/confirmed COVID-19, corresponding to a crude incidence rate of 20.4 and 26.9 per 1000 person-years, respectively.

During the study period there were 403 deaths (31 were COVID-19-related deaths) in the exposed group (MF+) and 275 (21 were COVID-19-related deaths) in the comparator group (MF−), corresponding to a crude incidence rate of 24.7 and 26.8 per 1000 person-years, respectively.

All-Cause Mortality and COVID-19-Related Death

During the study period there were 403 deaths (31 were COVID-19-related deaths) in the exposed group (MF+) and 275 (21 were COVID-19-related deaths) in the comparator group (MF−), corresponding to a crude incidence rate of 19.7 and 39.0 per 1000 person-years, respectively.

Following propensity score matching, 172 individuals (47 had confirmed COVID-19) in the exposed group (MF+) and 186 individuals (53 had confirmed COVID-19) in the comparator group were diagnosed with suspected/confirmed COVID-19, corresponding to a crude incidence rate of 24.7 and 26.8 per 1000 person-years, respectively.

In the exposed group (MF+) compared to the comparator group (MF−), the adjusted hazard ratio (HR) for primary care consultations for suspected/confirmed COVID-19 was 0.85 (95% CI, 0.67-1.08) and for confirmed COVID-19 was 0.80 (95% CI, 0.49-1.30) (Table 2). Kaplan-Meier curves for suspected/confirmed COVID-19 cases are presented in Fig. 2.
Figure 1. Flow chart.

All patients with a record of Type 2 Diabetes Mellitus in the dataset, with an index date later than 30th Jan 2020 and aged ≥18 years N = 131,341

Patients who are pregnant within one year before the index date, have a record of pancreatitis or recorded adverse reactions to glucose-lowering agents N = 2,705

Patients with a record of Type 1 Diabetes Mellitus or who were diagnosed as diabetes before 12 yrs N = 7,411

Total eligible cohort N = 118,306

Patients whose eGFR < 30mL/min/1.73m² N = 2,919

Absence of evidence of any glucose-lowering agent prescription during study period N = 21,986

Patients who are on a current metformin prescription N = 59,724

Patients who are on a current glucose-lowering agent prescription but not metformin N = 24,686

Patients who are on a current glucose-lowering agent prescription and co-prescribed at least one of the other glucose-lowering agents

Exposed group (MF+, N = 29,558)

Patients with metformin monotherapy N = 30,166

Comparator group (MF-, N = 10,271)

Patients with a prescription of metformin lasting within the 90 days preceding the index date (recent users) N = 1,639

Patients with a prescription of metformin lasting within the 90 days preceding the index date (recent users) N = 1,639

Propensity Score Matching

Matched Cohort

Exposed group: N = 10,183
Comparator group: N = 10,183

Other glucose-lowering agents were defined as individuals with a record of one of the following eight prescriptions: sodium/glucose co-transporter-2 inhibitors (SGLT2), dipeptidyl peptidase-4 inhibitor (DPP4), glucagon-like peptide-1 (GLP-1), insulin, sulfonylureas, meglitinides, thiazolidinedione, and acarbose.

* Details could be found in the Supplementary material, S3.(30)
Table 1. Baseline Demographic Characteristics, Behavioral Risk Factors, Diabetes Complications, Comorbidities, Metabolic Characteristics, and Medications

|                          | Unmatched | Propensity score–matchedb |
|--------------------------|-----------|---------------------------|
|                          | Exposed group (MF+) (n = 29 558) | Comparator group (MF−) (n = 10 271) | Exposed group (MF+) (n = 10 183) | Comparator group (MF−) (n = 10 183) |
| **Demographic characteristics** |           |                           |                               |                                   |
| Mean age, years (SD)     | 64.8 (11.7) | 67.8 (13.1)               | 67.2 (11.8)                  | 67.7 (13.1)                       |
| Male sex (%)             | 18 298 (61.9) | 5343 (52.0)               | 5297 (52.0)                  | 5326 (52.3)                       |
| Mean BMI, kg/m² (SD)     | 32.1 (6.70) | 31.8 (6.8)                | 31.9 (6.7)                   | 31.8 (6.8)                        |
| BMI category (%)         |           |                           |                               |                                   |
| <25                      | 3159 (10.7) | 1353 (13.2)               | 1199 (11.8)                  | 1338 (13.1)                       |
| 25 to <30                | 9080 (30.7) | 3067 (29.9)               | 3084 (30.3)                  | 3038 (29.8)                       |
| ≥30                      | 16 908 (57.2) | 5678 (55.3)               | 5706 (56.0)                  | 5639 (55.4)                       |
| Missing                  | 411 (1.4) | 173 (1.7)                 | 194 (1.9)                    | 168 (1.6)                         |
| **Behavioral risk factors** |           |                           |                               |                                   |
| Smoking status (%)       |           |                           |                               |                                   |
| Nonsmokers               | 14 632 (49.5) | 5105 (49.7)               | 4997 (49.1)                  | 5057 (49.7)                       |
| Ex-smokers               | 10 799 (36.5) | 3726 (36.3)               | 3710 (36.4)                  | 3701 (36.3)                       |
| Current smokers          | 4063 (13.7) | 1383 (13.5)               | 1432 (14.1)                  | 1373 (13.5)                       |
| Missing                  | 64 (0.2) | 57 (0.6)                  | 44 (0.4)                     | 52 (0.5)                          |
| Excessive alcohol use (%)| 1506 (5.1) | 668 (6.5)                 | 655 (6.4)                    | 657 (6.5)                         |
| Mean diabetes duration, years (SD) | 12.1 (6.7) | 11.6 (7.0)               | 11.6 (6.7)                   | 11.6 (7.0)                        |
| **Diabetes complications** |           |                           |                               |                                   |
| Peripheral neuropathy (%) | 2070 (7.0) | 784 (7.6)                 | 775 (7.6)                    | 776 (7.6)                         |
| Diabetic foot disease (%) | 1335 (4.5) | 527 (5.1)                 | 526 (5.2)                    | 518 (5.1)                         |
| Sight threatening retinopathy (%) | 3307 (11.9) | 1286 (12.5)               | 1244 (12.2)                  | 1264 (12.4)                       |
| **Comorbidities**        |           |                           |                               |                                   |
| Hypertension (%)         | 17 477 (59.1) | 6234 (60.7)               | 6091 (59.8)                  | 6178 (60.7)                       |
| Ischemic heart disease (%) | 5374 (18.2) | 2271 (22.1)               | 2216 (21.8)                  | 2237 (22.0)                       |
| Atrial fibrillation (%)  | 2194 (7.4) | 1101 (10.7)               | 1037 (10.2)                  | 1077 (10.6)                       |
| Stroke/TIA (%)           | 1992 (6.7) | 1001 (9.7)                | 944 (9.3)                    | 970 (9.5)                         |
| Heart failure (%)        | 1322 (4.5) | 764 (7.4)                 | 696 (6.8)                    | 745 (7.3)                         |
| Peripheral vascular disease (%) | 1055 (3.6) | 508 (4.9)                 | 492 (4.8)                    | 500 (4.9)                         |
| Chronic kidney disease (%) | 3839 (13.0) | 2481 (24.2)               | 1842 (18.1)                  | 2428 (23.8)                       |
| Cancers* (%)             | 3114 (10.5) | 1505 (14.7)               | 1481 (14.5)                  | 1474 (14.5)                       |
| Chronic respiratory disease (%) | 2351 (8.0) | 1031 (10.0)               | 1009 (9.9)                   | 1016 (10.0)                       |
| Liver disease (%)        | 1636 (5.5) | 624 (6.1)                 | 570 (5.6)                    | 619 (6.1)                         |
| Rheumatoid arthritis (%) | 442 (1.5) | 218 (2.1)                 | 220 (2.2)                    | 212 (2.1)                         |
| NAFLD/NASH (%)           | 742 (2.5) | 263 (2.6)                 | 262 (2.6)                    | 261 (2.6)                         |
| Blood & bone marrow cancer (%) | 404 (1.4) | 163 (1.6)                 | 165 (1.6)                    | 162 (1.6)                         |
| **Metabolic characteristics** |           |                           |                               |                                   |
| Diastolic BP (mmHg) <90  | 27 474 (92.9) | 9530 (92.8)               | 9478 (93.1)                  | 9450 (92.8)                       |
| ≥90                      | 2052 (6.9) | 727 (7.1)                 | 689 (6.8)                    | 720 (7.1)                         |
| Missing                  | 32 (0.1) | 14 (0.1)                  | 16 (0.2)                     | 13 (0.1)                          |
| Systolic BP (mmHg) <140  | 21 102 (71.4) | 7120 (69.3)               | 7078 (69.5)                  | 7073 (69.5)                       |
| ≥140                     | 8424 (28.5) | 3137 (30.5)               | 3089 (30.3)                  | 3097 (30.4)                       |
| Missing                  | 32 (0.1) | 14 (0.1)                  | 16 (0.2)                     | 13 (0.1)                          |
Table 1. Continued

|                      | Exposed group (MF+) (n = 29 558) | Comparator group (MF−) (n = 10 271) | Exposed group (MF+) (n = 10 183) | Comparator group (MF−) (n = 10 183) |
|----------------------|----------------------------------|-----------------------------------|----------------------------------|-----------------------------------|
| **Total cholesterol (mmol/L)** |                                  |                                   |                                  |                                   |
| <5.2                 | 25 257 (85.4)                    | 8106 (78.9)                       | 8137 (79.9)                      | 8064 (79.2)                       |
| 5.2 to 6.2           | 2878 (9.7)                       | 1388 (13.5)                       | 1251 (12.3)                      | 1367 (13.4)                       |
| ≥6.2                 | 1252 (4.2)                       | 696 (6.8)                         | 725 (7.1)                        | 675 (6.6)                         |
| Missing              | 171 (0.6)                        | 81 (0.8)                          | 70 (0.7)                         | 77 (0.8)                          |
| **HDL-cholesterol (mmol/L)** |                                  |                                   |                                  |                                   |
| <1.55                | 26 054 (88.1)                    | 8736 (85.1)                       | 8757 (86.0)                      | 8669 (85.1)                       |
| ≥1.55                | 3028 (10.2)                      | 1312 (12.8)                       | 1239 (12.2)                      | 1296 (12.7)                       |
| Missing              | 476 (1.6)                        | 223 (2.2)                         | 187 (1.8)                        | 218 (2.1)                         |
| **eGFR (mL/min/1.73m²)** |                                  |                                   |                                  |                                   |
| ≥60 (Stage 1&2)      | 24 469 (82.8)                    | 7280 (70.9)                       | 7597 (74.6)                      | 7258 (71.3)                       |
| 30 to 60 (Stage 3)   | 4991 (16.9)                      | 2950 (28.7)                       | 2551 (25.1)                      | 2885 (28.3)                       |
| Missing              | 98 (0.3)                         | 41 (0.4)                          | 35 (0.3)                         | 40 (0.4)                          |
| **ACR (mg/mmol)**    |                                  |                                   |                                  |                                   |
| <3 mg/mmol           | 15 119 (51.2)                    | 4851 (47.2)                       | 4909 (48.2)                      | 4819 (47.3)                       |
| 3 to 30 mg/mmol      | 6144 (20.8)                      | 2274 (22.1)                       | 2294 (22.5)                      | 2258 (22.2)                       |
| ≥30 mg/mmol          | 1052 (3.6)                       | 481 (4.7)                         | 460 (4.5)                        | 470 (4.6)                         |
| Missing              | 7243 (24.5)                      | 2665 (25.9)                       | 2520 (24.7)                      | 2636 (25.9)                       |
| **HbA1c (mmol/mol)** |                                  |                                   |                                  |                                   |
| <48 mmol/mol (6.5%)  | 26 54 (9.0)                      | 1048 (10.2)                       | 879 (8.6)                        | 1042 (10.2)                       |
| 48 to 58 mmol/mol (6.5–7.5%) | 7918 (26.8)                      | 2645 (25.8)                       | 2618 (25.7)                      | 2624 (25.8)                       |
| ≥58 mmol/mol (7.5%)  | 18 461 (62.5)                    | 6429 (62.6)                       | 6489 (63.7)                      | 6369 (62.5)                       |
| Missing              | 525 (1.8)                        | 149 (1.5)                         | 197 (1.9)                        | 148 (1.5)                         |
| **Medications**      |                                  |                                   |                                  |                                   |
| Metformin (%)        |                                  |                                   |                                  |                                   |
| Current users        | 29 558 (100.0)                   | 0 (0.0)                           | 10 183 (100.0)                   | 0 (0.0)                           |
| Recent users         | 0 (0.0)                          | 0 (0.0)                           | 0 (0.0)                          | 0 (0.0)                           |
| Historical users     | 0 (0.0)                          | 8640 (84.1)                       | 0 (0.0)                          | 8587 (84.3)                       |
| Nonusers             | 0 (0.0)                          | 1631 (15.9)                       | 0 (0.0)                          | 1596 (15.7)                       |
| DPP4i (%)            |                                  |                                   |                                  |                                   |
| Current users        | 13 132 (44.4)                    | 4249 (41.4)                       | 4170 (41.0)                      | 4222 (41.5)                       |
| Recent users         | 364 (1.2)                        | 147 (1.4)                         | 138 (1.4)                        | 146 (1.4)                         |
| Historical users     | 4985 (16.9)                      | 1809 (17.6)                       | 1773 (17.4)                      | 1795 (17.6)                       |
| Nonusers             | 11 077 (37.5)                    | 4066 (39.6)                       | 4102 (40.3)                      | 4020 (39.5)                       |
| SGLT2i (%)           |                                  |                                   |                                  |                                   |
| Current users        | 10 661 (36.1)                    | 2784 (27.1)                       | 2871 (28.2)                      | 2780 (27.3)                       |
| Recent users         | 278 (0.9)                        | 103 (1.0)                         | 97 (1.0)                         | 102 (1.0)                         |
| Historical users     | 2053 (7.0)                       | 844 (8.2)                         | 835 (8.4)                        | 836 (8.2)                         |
| Nonusers             | 16 564 (56.0)                    | 6540 (63.7)                       | 6360 (62.5)                      | 6465 (63.5)                       |
| Meglitinides (%)     |                                  |                                   |                                  |                                   |
| Current users        | 60 (0.2)                         | 13 (0.1)                          | 10 (0.1)                         | 13 (0.1)                          |
| Recent users         | 6 (0.0)                          | 0 (0.0)                           | 0 (0.0)                          | 0 (0.0)                           |
| Historical users     | 306 (1.0)                        | 121 (1.2)                         | 121 (1.2)                        | 118 (1.2)                         |
| Nonusers             | 29 186 (98.7)                    | 10 137 (98.7)                     | 10 052 (98.7)                    | 10 052 (98.7)                     |
| Acarbose (%)         |                                  |                                   |                                  |                                   |
| Current users        | 42 (0.1)                         | 15 (0.1)                          | 15 (0.1)                         | 15 (0.1)                          |
| Recent users         | 4 (0.0)                          | 1 (0.0)                           | 1 (0.0)                          | 1 (0.0)                           |
| Historical users     | 219 (0.7)                        | 105 (1.0)                         | 112 (1.1)                        | 103 (1.0)                         |
| Nonusers             | 29 293 (99.1)                    | 10 150 (98.8)                     | 10 055 (98.7)                    | 10 064 (98.8)                     |
| GLP1 (%)             |                                  |                                   |                                  |                                   |
| Current users        | 2081 (7.0)                       | 588 (5.7)                         | 618 (6.1)                        | 586 (5.8)                         |
| Recent users         | 597 (2.0)                        | 157 (1.5)                         | 160 (1.6)                        | 156 (1.5)                         |
statistically significant difference was observed between the groups for the risk of all-cause mortality (adjusted HR 0.89; 95% CI, 0.74-1.07) or COVID-19-related death (adjusted HR 0.87; 95% CI, 0.34-2.20).

**Back Pain (Negative Outcome)**

Among individuals who were free of back pain at study entry, there were 119 and 51 individuals in the exposed (MF+) and the comparator group (MF−) diagnosed with back pain during the follow-up period, respectively.

In the propensity score–matched cohort, 107 individuals in the exposed group (MF+) and 108 individuals in the comparator group were patients with incident back pain, which translated to an adjusted HR of 1.01 (95% CI, 0.73-1.39).

The results were broadly similar in the sensitivity analyses as well as the subgroup analyses (Supplementary files S5-S7) (30).

**Discussion**

Type 2 diabetes has been identified as a predictor of severe COVID-19 and mortality (3, 34, 35). However, little is currently known about which specific glucose-lowering agents can be used to safely maintain or improve glycemic control amid the COVID-19 pandemic (3, 36). In our primary care–based study, we found that patients with type 2 diabetes who received a prescription of metformin (plus other glucose-lowering agents) within 90 days of the study start period were not more likely to present to primary care with confirmed or suspected COVID-19-related disease.

| Table 1. Continued |
|---------------------|
| **Unmatched** | **Propensity score–matched** |
| | Exposed group | Comparator group | Exposed group | Comparator group |
| | (MF+ (n = 29 558) | (MF− (n = 10 271) | (MF+ (n = 10 183) | (MF− (n = 10 183) |
| Historical users | 2910 (9.8) | 960 (9.3) | 1018 (10.0) | 954 (9.4) |
| Nonusers | 23 970 (81.1) | 8366 (83.4) | 8387 (82.4) | 8487 (83.3) |
| **Insulin (%)** | | | | |
| Current users | 1901 (6.4) | 1029 (10.0) | 1005 (9.9) | 1006 (9.9) |
| Recent users | 859 (2.9) | 361 (3.5) | 338 (3.5) | 360 (3.5) |
| Historical users | 2613 (8.8) | 1193 (11.6) | 1149 (11.3) | 1169 (11.5) |
| Nonusers | 24 185 (81.8) | 7688 (74.9) | 7671 (75.3) | 7648 (75.1) |
| **Thiazolidinedione (%)** | | | | |
| Current users | 1683 (5.7) | 547 (5.3) | 541 (5.3) | 542 (5.3) |
| Recent users | 69 (0.2) | 32 (0.3) | 34 (0.3) | 32 (0.3) |
| Historical users | 4422 (15.0) | 1404 (13.7) | 1437 (14.1) | 1388 (13.6) |
| Nonusers | 23 384 (79.1) | 8288 (80.7) | 8171 (80.2) | 8221 (80.7) |
| **Sulphonylureas (%)** | | | | |
| Current users | 12 979 (43.9) | 4510 (43.9) | 4457 (43.8) | 4473 (43.9) |
| Recent users | 563 (1.9) | 233 (2.3) | 226 (2.2) | 231 (2.3) |
| Historical users | 6563 (21.5) | 2523 (24.6) | 2479 (24.3) | 2491 (24.5) |
| Nonusers | 9631 (32.7) | 3005 (29.3) | 3021 (29.7) | 2988 (29.3) |
| **Immunosuppressive drugs (%)** | | | | |
| Current users | 1070 (3.6) | 592 (5.8) | 548 (5.4) | 578 (5.7) |
| Recent users | 69 (0.2) | 361 (3.5) | 358 (3.5) | 360 (3.5) |
| Historical users | 4422 (15.0) | 1404 (13.7) | 1437 (14.1) | 1388 (13.6) |
| Nonusers | 23 384 (79.1) | 8288 (80.7) | 8171 (80.2) | 8221 (80.7) |

**Exposure group:** patients with a current combination prescription of metformin and other glucose-lowering agents; **Comparator group:** patients with a current prescription of other glucose-lowering agents.

Abbreviations: ACEi, angiotensin-converting enzyme inhibitor; ACR, albumin-creatinine ratio; ARB, angiotensin receptor blocker; BMI, body mass index; BP, blood pressure; DPP4i, dipeptidyl peptidase-4 inhibitors; eGFR, estimated glomerular filtration rate; GLP1, glucagon-like peptide 1 receptor agonist; HbA1c, glycated hemoglobin A1c; HDL, high-density lipoprotein; NAFLD/NASH, nonalcoholic fatty liver disease/nonalcoholic steatohepatitis; SGLT2i, sodium-glucose cotransporter-2 inhibitors; TIA, transient ischemic attack.

aExcluding melanoma, and blood and bone marrow cancers

bData were presented for the first multiple imputed propensity score–matched cohort.
Table 2. Risk of Developing COVID-19, Mortality, and Back Pain Among Those With a Current Combination Prescription of Metformin and Other Glucose-Lowering Agents Compared With a Current Prescription of Other Glucose-Lowering Agents Only

|                        | Confirmed COVID-19 | Suspected/Confirmed COVID-19 | COVID-19-related death | All-cause mortality | Back pain |
|------------------------|--------------------|-----------------------------|------------------------|---------------------|-----------|
|                        | Exposed group (MF+) | Comparator group (MF−)      | Exposed group (MF+)   | Comparator group (MF−) | Exposed group (MF+) | Comparator group (MF−) | Exposed group (MF+) | Comparator group (MF−) | Exposed group (MF+) | Comparator group (MF−) |
| **Unmatched analysis** |                    |                             |                        |                     |                        |                        |                        |                        |                        |                        |
| Total number of patients | 29,558             | 10,271                      | 29,558                 | 10,271              | 29,558                 | 10,271                 | 29,558                 | 10,271                 | 29,558                 | 10,271                 |
| Number of outcomes     | 110                | 54                          | 415                    | 188                 | 31                     | 21                     | 403                    | 275                    | 315                    | 109                    |
| Person-years (py)      | 20,454             | 70,38                       | 20,351                 | 69,93               | 20,486                 | 70,55                   | 20,486                 | 70,55                   | 20,364                 | 70,10                   |
| Incidence rate (per 1000 py) | 5.4                | 7.7                         | 20.4                   | 26.9               | 1.5                    | 3.0                     | 19.7                   | 39.0                   | 15.5                   | 15.6                   |
| Crude hazard ratio (95% CI) | 0.70 (0.51, 0.97)  | 0.76 (0.64, 0.90)           | 0.51 (0.29, 0.89)     | 0.51 (0.43, 0.59)   | 1.00 (0.80, 1.24)      |                        |                        |                        |                        |                        |
| Adjusted HR (95% CI)   | 0.75 (0.54, 1.04)  | 0.80 (0.67, 0.96)           | 0.74 (0.42, 1.32)     | 0.72 (0.62, 0.85)   | 1.01 (0.81, 1.26)      |                        |                        |                        |                        |                        |
| **Matched analysis**   |                    |                             |                        |                     |                        |                        |                        |                        |                        |                        |
| Total number of patients | 10,183             | 10,183                      | 10,183                 | 10,183              | 10,183                 | 10,183                  | 10,183                 | 10,183                  | 10,183                 | 10,183                  |
| Number of outcomes b   | 47                 | 47                          | 172                    | 186                 | 17                     | 20                     | 214                    | 266                    | 107                    | 108                    |
| Person-years (py) b    | 70,10              | 69,80                       | 69,69                  | 69,35               | 70,23                   | 69,98                   | 70,23                   | 69,98                   | 69,81                   | 69,52                   |
| Incidence rate (per 1000 py) b | 6.7                | 7.6                         | 24.7                   | 26.8               | 2.4                    | 2.9                     | 30.5                   | 38.0                   | 15.3                   | 15.5                   |
| Crude hazard ratio (95% CI) b | 0.78 (0.48, 1.28)  | 0.85 (0.67, 1.08)           | 0.76 (0.29, 1.97)     | 0.79 (0.66, 0.95)   | 1.01 (0.73, 1.39)      |                        |                        |                        |                        |                        |
| Adjusted HR (95% CI) a b | 0.80 (0.49, 1.30)  | 0.85 (0.67, 1.08)           | 0.87 (0.34, 2.20)     | 0.89 (0.74, 1.07)   | 1.01 (0.73, 1.39)      |                        |                        |                        |                        |                        |

Exposed group: patients with a current combination prescription of metformin and other glucose-lowering agents; Comparator group: patients with a current prescription of other glucose-lowering agents

*Adjusted for: age, sex, smoking status, high alcohol consumption (alcoholism), body mass index categories, total cholesterol categories, high-density lipoprotein categories, albumin-creatinine ratio categories, estimated glomerular filtration rate categories, HbA1c categories, atrial fibrillation, rheumatoid arthritis, hypertension, cardiovascular disease, nonalcoholic fatty liver disease or nonalcoholic steatohepatitis, prescriptions of renin-angiotensin-aldosterone system inhibitors, other antihypertensive drugs, lipid-lowering drugs, antiplatelets, anticoagulants, diabetes complications, diabetes duration, respiratory disease, cancers, immunosuppressant therapies, and systemic corticosteroid use.

*bData were presented for the first multiple imputed propensity score-matched cohort.
compared with those not taking metformin. There was no significant increase in COVID-19-related mortality or all-cause mortality.

**Relationship to Other Studies**

There are currently no comparable studies in the published or preprint literature investigating the association between therapeutic prescription of metformin and primary care consultation for symptomatic COVID-19. Several observational studies have examined the association between mortality from COVID-19 and taking metformin in more severely affected hospitalized patients and have suggested a reduction in risk (15, 16). Our findings in primary care are in line with those reported by Bramante et al from a propensity score-matched observational study of mortality in over 6000 US patients hospitalized with COVID-19, which found that metformin had no effect on in-hospital mortality in patients with type 2 diabetes or obesity (17). However, Bramante et al found lower in-hospital mortality with COVID-19 in women taking metformin (OR 0.76; 95% CI, 0.60-0.96), while there was no significant reduction in mortality for men (17). In our study, we found susceptibility to COVID-19 was statistically significant lower (adjusted HR

**Figure 2.** Kaplan-Meier plot showing the risk of suspected/confirmed COVID-19 in the unmatched and matched analysis.
The results of previous relevant studies and our study on the association between metformin use and COVID-19-related mortality have been shown in Fig. 3 (4, 7, 17, 18, 37-40).

The pathobiology of any interaction between COVID-19 and metformin is incompletely understood but may be affected by factors that impact the ability of the virus to enter host cells, the ability of the host to clear the virus through disease resistance mechanisms, and host ability to withstand a deterioration in organ function through disease tolerance mechanisms (41). Firstly, metformin may prevent or reduce the SARS-CoV-2 virus from entering cells (20). It may decrease potentially harmful levels of proinflammatory cytokines which drive hyperinflammation through macrophage M1 to M2 class switching (42-44). Furthermore, metformin has been shown to potentially inhibit checkpoint inhibitor upregulation which may be important to avoid T-cell anergy and promote clearance of SARS-CoV-2 (44, 45). However, the AMPK-mediated immunomodulatory effects of metformin via the antiviral interferon pathway have also been noted to impair antibody responses following vaccination in people with diabetes so that the net effect of metformin in terms of propensity to develop or die from COVID-19 is neutral (46), as we have found.

Strengths and Limitations
Our study included a large cohort and the study period covers the majority of the pandemic duration in the UK to date. The proportion of missing variables was low. We used a propensity score–matched design in order to minimize any effects due to differences between the exposed and unexposed groups, due to or confounding by indication bias. Furthermore, we adjusted for a range of potential confounders and included a negative control outcome in our analyses.

However, there are several important limitations. The data quality is reliant on accurate coding by general practitioners and administrative staff in primary care, including coding of hospital discharge letters sent to primary care services for patients with suspected or confirmed COVID-19. In the UK, all patients with type 2 diabetes are entitled to free and easily accessible prescription of glucose-lowering agents (prescription-only medications) from their general practitioner. Only an extremely small proportion of patients would receive their care through the private sector, therefore this would not have a significant impact on the generalizability of our results. Recording of medication prescriptions is known to be very reliable in this primary care dataset, with very few patients not accessing them via their NHS general practitioner. However, it is possible that patients are not compliant with their medication. The event rate for some outcomes, such as confirmed COVID-19 cases and COVID-19-related deaths, was relatively low, limiting statistical power to detect small effects in these outcomes. Although the groups were well matched for multiple factors that could affect the outcome, there remained some imbalance with respect to eGFR/chronic kidney disease status, which is known to impact COVID-19 outcomes (34); however, eGFR was adjusted for in the regression models. We did not have data on hospitalization status, patient ethnicity, or socioeconomic status. It is not possible to completely rule out unmeasured confounding.

Although we found no significant harm or benefit of metformin, the study was not designed to assess the effects of metformin on COVID-19 outcomes in patients who

| Studies                  | Population       | N    | OR (95% CI) |
|--------------------------|------------------|------|-------------|
| Population-based study   |                  |      |             |
| Our study                | Type 2 Diabetes (T2DM) | 20,366 | HR 0.87 (0.34, 2.20) |
| Hospital-based studies   |                  |      |             |
| Bramante et al. 2020     | COVID-19 & T2DM/obesity | 6,256 | HR 0.90 (0.77, 1.05) |
| Carlous et al. 2020      | COVID-19 & T2DM   | 1,317 | 0.80 (0.45, 1.43)  |
| Cheng et al. 2020        | COVID-19 & T2DM   | 1,213 | 0.87 (0.36, 2.12)  |
| Luo et al. 2020          | COVID-19 & T2DM   | 283  | 0.23 (0.06, 0.82)  |
| Crouse et al. 2020       | COVID-19 & T2DM   | 239  | 0.33 (0.13, 0.84)  |
| Chen et al. 2020         | COVID-19 & T2DM   | 120  | 0.48 (0.17, 1.35)  |
| Gao et al. 2020          | COVID-19 & T2DM   | 110  | 3.96 (1.03, 15.19) |
| Wong et al. 2020         | COVID-19          | 58   | 0.35 (0.01, 3.08)  |

Figure 3. Forest plots showing the results of previous similar studies on the association between metformin use and COVID-19-related mortality.
do not have type 2 diabetes. Consequently, it remains unclear whether metformin could benefit any specific groups of patients without diabetes (eg, those with obesity, or prediabetes) in the context of COVID-19.

**Recommendations for Primary Care**

Our findings show that metformin did not significantly influence susceptibility to COVID-19 no mortality from it among people with type 2 diabetes in the UK primary care setting. This is important, as a majority of patients with type 2 diabetes are prescribed metformin (47). For many patients, metformin is crucial to optimizing glycemic control and weight management, and it has a long-established efficacy and safety profile (48). Our data, in conjunction with those from hospitalized patients, demonstrate that patients who are prescribed long-term metformin and are currently well can be reassured that it is safe to continue consumption. Adherence to usual guidance on sick-day rules, however, remains strongly advised if the patient is at risk of dehydration (22, 23). Clinicians should advise patients taking metformin who develop symptoms consistent with COVID-19 (or indeed any infection) to withhold this medication if there are concerns about acidosis and to consider increased monitoring of blood glucose for the duration of the illness (23).

**Conclusion**

Our findings suggest that prescription of metformin in primary care does not influence susceptibility to COVID-19, COVID-19-related mortality, or all-cause mortality. This is reassuring given that patients with diabetes are more susceptible to mortality with COVID-19, and that metformin is the most commonly prescribed glucose-lowering medication. Optimizing glycemic control should continue to be the best advice for patients with diabetes, especially if rates of COVID-19 rise.

**Acknowledgments**

J.W. is the guarantor of this manuscript.

**Financial Support:** The authors have no financial relationships relevant to this article to disclose.

**Additional Information**

**Correspondence:** Neil Thomas, PhD, Institute of Applied Health Research, University of Birmingham, Birmingham B15 2TT, UK.

Email: g.n.thomas@bham.ac.uk

Disclosures: The authors have no conflicts of interest relevant to this article to disclose.

Data Availability: The datasets generated during and/or analyzed during the current study are not publicly available but are available from the corresponding author on reasonable request.

**References**

1. Popkin BM, Du S, Green WD, et al. Individuals with obesity and COVID-19: A global perspective on the epidemiology and biological relationships. *Obes. Rev.* 2020;21(11):e13128.

2. Johns Hopkins University & Medicine Center for Systems Science and Engineering. COVID-19 Dashboard Global Map. https://coronavirus.jhu.edu/map.html. Accessed February 19, 2021.

3. Barron E, Bakhai C, Kar P, et al. Associations of type 1 and type 2 diabetes with COVID-19-related mortality in England: a whole-population study. *Lancet Diabetes Endocrinol.* 2020;8(10):813-822.

4. Cariou B, Hadjadji S, Wargny M, et al. Phenotypic characteristics and prognosis of inpatients with COVID-19 and diabetes: the CORONADO study. *Diabetologia.* 2020;63(8):1500-1515.

5. Yaribeygi H, Atkin SL, Pirro M, Sahebkar A. A review of the anti-inflammatory properties of antidiabetic agents providing protective effects against vascular complications in diabetes. *J Cell Physiol.* 2019;234(6):8286-8294.

6. Shi Q, Zhang X, Jiang F, et al. Clinical characteristics and risk factors for mortality of COVID-19 patients with diabetes in Wuhan, China: a two-center, retrospective study. *Diabetes Care.* 2020;43(7):1382-1391.

7. Chen Y, Yang D, Cheng B, et al. Clinical characteristics and outcomes of patients with diabetes and COVID-19 in association with glucose-lowering medication. *Diabetes Care.* 2020;43(7):1399-1407.

8. Zhang M, He J-Q. Impacts of metformin on tuberculosis incidence and clinical outcomes in patients with diabetes: a systematic review and meta-analysis. *Eur J Clin Pharmacol.* 2020;76(2):149-159.

9. Ho TW, Huang CT, Tsai YJ, Lien AS, Lai F, Yu CJ. Metformin use mitigates the adverse prognostic effect of diabetes mellitus in chronic obstructive pulmonary disease. *Respir Res.* 2019;20(1):69.

10. Mortensen E, Anzueto A. Association of metformin and mortality for patients with diabetes who are hospitalized with pneumonia. *Eur Respir J.* 2018;52(Suppl 62):2639.

11. Wu TD, Keet CA, Fawzy A, Segal JB, Brigham EP, McCormack MC. Association of metformin initiation and risk of asthma exacerbation: a claims-based cohort study. *Ann Am Thorac Soc.* 2019;16(12):1527-1533.

12. Liang H, Ding X, Li L, et al. Association of prediabetes metformin use and mortality in patients with sepsis and diabetes mellitus: a systematic review and meta-analysis of cohort studies. *Crit Care.* 2019;23(1):50.

13. UK Prospective Diabetes Study Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). *Lancet.* 1998;352(9131):854-865.

14. Kow CS, Hasan SS. Mortality risk with prediabetes metformin use in patients with COVID-19 and diabetes: A meta-analysis. *J Med Virol.* 2020;92(2):695-697.

15. Hariyanto TI, Kurniawan A. Metformin use is associated with reduced mortality rate from coronavirus disease 2019 (COVID-19) infection. *Obes Med.* 2020;19:100290.
16. Wu Z, McGoo gang JM. Characteristics of and important less- 
sons from the Coronavirus disease 2019 (COVID-19) out-
break in China: summary of a report of 72 314 cases from the
Chinese Center for Disease Control and Prevention. JAMA.
2020;323(13):1239-1242.
17. Bramante C, Ingraham N, Murray T, et al. Observational study 
of metformin and risk of mortality in patients hospitalized with
Covid-19. MedRxiv. 2020.
18. Cheng X, Liu Y-M, Li H, et al. Metformin is associated with
higher incidence of acidosis, but not mortality, in individuals 
with COVID-19 and pre-existing type 2 diabetes. Cell Metab.
2020;32(4):537-547.
19. Liu J, Li X, Lu Q, et al. AMPK: a balancer of the renin–angio-
tensin system. Biosci Rep. 2019;39(9):BRS20181994.
20. Sharma S, Ray A, Sadasivan B. Metformin in COVID-19: A
possible role beyond diabetes. Diabetes Res Clin Pract.
2020;164:108183.
21. Ursini F, Ciaffi J, Landini MP, Meliconi R. COVID-19 and dia-
betes: is metformin a friend or foe? Diabetes Res Clin Pract
2020;164:1-2.
22. Duong JK, Furlong TJ, Roberts DM, et al. The role of 
Metformin in Metformin-Associated Lactic Acidosis (MALA):
case series and formulation of a model of pathogenesis. Drug 
Saf. 2013;36(9):733-746.
23. NHS England and NHS Improvement London. Sick day 
rules: how to manage Type 2 diabetes if you become unwell 
with coronavirus and what to do with your medication 2020.
https://www.england.nhs.uk/london/wp-content/uploads/sites/8/2020/04/3.-Covid-19-Type-2-Sick-Day-Rules-Crib-
Sheet-06042020.pdf. Accessed February 19, 2021.
24. Sainsbury C, Wang J, Gokhale K, et al. Sodium-glucose-co-
transporter-2 inhibitors and susceptibility to COVID-19: a 
population-based retrospective cohort study. Diabetes Obes 
Metab. 2020;23(1):263-269.
25. Blak BT, Thompson M, Dattani H, Bourke A. Generalisability 
of The Health Improvement Network (THIN) database: demo-
graphics, chronic disease prevalence and mortality rates. Inform 
Prim Care. 2011;19(4):251-255.
26. Robinson D, Schulz E, Brown P, Price C. Updating the Read 
Codes: user-interactive maintenance of a dynamic clinical vo-
culary. J Am Med Inform Assoc. 1997;4(6):465-472.
27. Spiers I, Goulding J, Arrowsmith I. Clinical terminologies in the
NHS: SNOMED CT and dm+ d. Br J Pharmacol. 2017;2(1):80.
28. Maguire A, Blak BT, Thompson M. The importance of defining 
periods of complete mortality reporting for research using auto-
mated data from primary care. Pharmacoepidemiol Drug Saf.
2009;18(1):76-83.
29. Lewis JD, Schinnar R, Bilker WB, Wang X, Strom BL. Validation 
studies of the health improvement network (THIN) database for 
pharmacoepidemiology research. Pharmacoepidemiol Drug Saf.
2007;16(4):393-401.
30. Wang J, Cooper JM, Gokhale K, et al. Supplementary file. 
GitHub. Posted January 20, 2021. https://github.com/viviansoar/GitHub-Share/blob/main/Supplementary%20file.pdf.
31. Sussa S, Moodie EE, Dell’Aniello S. Prevalent new-user cohort de-
signs for comparative drug effect studies by time-conditional pro-
pensity scores. Pharmacoepidemiol Drug Saf. 2017;26(4):459-468.
32. Austin PC. Optimal caliper widths for propensity-score match-
ing when estimating differences in means and differences in proportions in observational studies. Pharm Stat.
2011;10(2):150-161.
33. Sanderson E, Macdonald-Wallis C, Davey Smith G. Negative 
control exposure studies in the presence of measurement error: 
implications for attempted effect estimate calibration. Int J 
Epidemiol. 2018;47(2):587-596.
34. Williamson EJ, Walker AJ, Bhaskaran K, et al. Factors associ-
ated with COVID-19-related death using OpenSAFELY. Nature.
2020;584(7821):430-436.
35. Zhu L, She Z-G, Cheng X, et al. Association of blood glucose 
control and outcomes in patients with COVID-19 and pre-
exisiting type 2 diabetes. Cell Metab. 2020;31(6):1068-1077.
36. Ceriello A, Stoian AP, Rizzo M. COVID-19 and diabetes man-
gement: What should be considered? Diabetes Res Clin Pract.
2020;163:1-2.
37. Crouse A, Grimes T, Li P, Might M, Ovalle E, Shalev A. 
Metformin use is associated with reduced mortality in a di-
verse population with COVID-19 and diabetes. medRxiv.
2020.
38. Gao Y, Liu T, Zhong W, et al. Risk of metformin in type 2 dia-
betes patients with COVID-19: a preliminary retrospective re-
port. Clin Transl Sci. 2020.
39. Luo P, Qiu L, Liu Y, et al. Metformin treatment was associated 
with decreased mortality in COVID-19 patients with diabetes in 
a retrospective analysis. Am J Trop Med Hyg. 2020: Doi: 
https://doi.org/10.1002/tpmd.2003757.
40. Wang B, Van Oekelen O, Mouhieddine TH, et al. A tertiary 
center experience of multiple-myeloma patients with COVID-
19: lessons learned and the path forward. J Hematol Oncol.
2020;13(1):1-12.
41. Schneider DS, Ayres JS. Two ways to survive infection: what re-
sistance and tolerance can teach us about treating infectious dis-
eses. Nat Rev Immunol. 2008;8(11):889-895.
42. Kelly B, Tannahill GM, Murphy MP, O’Neill LA. Metformin
inhibits the production of reactive oxygen species from
NADH:ubiquinone oxidoreductase to limit induction of
interleukin-1β (IL-1β) and boosts interleukin-10 (IL-10) in
lipopolysaccharide (LPS)-activated macrophages. J Biol Chem.
2015;290(33):20348-20359.
43. Del Valle DM, Kim-Schulze S, Huang HH, et al. An inflamma-	ory cytokine signature predicts COVID-19 severity and sur-
vival. Nat Med. 2020;26(10):1636-1643.
44. Cha JH, Yang WH, Xia W, et al. Metformin promotes antitumor
immunity via endoplasmic-reticulum-associated degradation of 
PD-L1. Mol Cell. 2018;71(4):606-620.e7.
45. Zheng M, Gao Y, Wang G, et al. Functional exhaustion of anti-
viral lymphocytes in COVID-19 patients. Cell Mol Immunol.
2020;17(5):533-535.
46. Saenwongsu W, Nithichanon A, Chittaganitch M, et al.
Metformin-induced suppression of IFN-α via mTORC1
signalling following seasonal vaccination is associated with
impaired antibody responses in type 2 diabetes. J Hematol Oncol.
2020;13(1):1-12.
47. ClinCalc LLC. Metformin hydrochloride: drug usage
statistics, United States, 2007–2017. Updated January
18, 2021. https://clincalc.com/DrugStats/Drugs/MetforminHydrochloride
48. Srinivasan B, Taub N, Khunti K, Davies M. Diabetes: glycemic
control in type 2. BMJ Clin. Evid. 2008;2008;0609.